What is the preferred method for gastrointestinal screening in a patient with potential tuberculosis exposure or diagnosis, Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT)?

FIT is Superior to FOBT for Colorectal Cancer Screening

The Fecal Immunochemical Test (FIT) should be used instead of guaiac-based Fecal Occult Blood Test (gFOBT) for colorectal cancer screening in all average-risk patients, including those with tuberculosis exposure or diagnosis, as FIT demonstrates superior sensitivity for both colorectal cancer and advanced neoplasia while maintaining comparable specificity. 1, 2

Why FIT Outperforms FOBT

Detection Accuracy

• FIT detects colorectal cancer with approximately twice the sensitivity of gFOBT (76-89% vs 30-65%), meaning FIT catches significantly more cancers 3, 4, 5
• For advanced neoplasia detection, FIT sensitivity ranges from 26-33% compared to only 15% for gFOBT 5
• In practical terms: among 100 patients with colorectal cancer, gFOBT misses 61 cases while FIT misses only 11-24 cases 5
• Specificity remains comparable between tests (93-97% for FIT vs 94-98% for gFOBT), so false-positive rates are similar 1, 5

Patient Compliance and Participation

• FIT achieves 10-20% higher participation rates than gFOBT because it requires fewer samples (1-2 vs 3) and no dietary restrictions 4, 6, 7
• In a large Veterans Administration study, FIT completion rate was 42.6% compared to only 33.4% for gFOBT 7
• The number needed to invite to achieve one additional completed test is only 11 patients when switching from gFOBT to FIT 7

Technical Advantages

• FIT specifically detects human globin protein, making it more accurate for lower GI bleeding 4
• Unlike gFOBT, FIT is not affected by dietary factors (red meat, vitamin C) or upper GI bleeding, reducing false results 4, 8
• Quantitative FIT allows adjustment of hemoglobin cutoff thresholds to balance sensitivity and specificity based on colonoscopy resources 2, 9

Guideline Recommendations

Primary Screening Strategy

• The American College of Physicians recommends FIT or high-sensitivity gFOBT every 2 years, colonoscopy every 10 years, or flexible sigmoidoscopy every 10 years plus FIT every 2 years 1
• The US Multi-Society Task Force on Colorectal Cancer provides a strong recommendation for FIT over gFOBT based on high-quality evidence 2
• Annual single-sample FIT is the preferred stool-based approach (weak recommendation, low evidence) 2

Specific FIT Implementation

• Use quantitative FIT over qualitative FIT to allow threshold adjustment 2
• Lower hemoglobin cutoff values (≤20 μg Hb/g feces) are favored to maximize cancer detection 2
• No dietary or medication restrictions are needed before FIT testing 2
• Avoid using digital rectal examination samples—only spontaneously passed stool should be used 2

Clinical Performance in Real-World Settings

Detection Rates

• When Scotland transitioned from gFOBT to FIT nationally, uptake increased from 56.4% to 63.9% and positivity increased from 2.2% to 3.1% 6
• Advanced neoplasia detection increased from 0.28% with gFOBT to 0.79% with FIT in the Veterans Administration study 7
• The positive predictive value for advanced adenomas is higher with FIT (24.3%) than gFOBT (19.3%) 6

Important Caveat About Cancer Detection

• While FIT sensitivity for cancer is 73-88%, this means 12-27% of cancers are still missed with a single FIT 3
• FIT has poor sensitivity (approximately 5%) for sessile serrated polyps, an important limitation 3, 4
• Multiple rounds of annual or biennial testing improve cumulative sensitivity over time 3

Follow-Up After Positive Results

Mandatory Colonoscopy

• Any positive FIT result requires colonoscopy—never repeat the FIT, as this inappropriately delays necessary evaluation 3, 4
• Colonoscopy should be completed within 270 days; delays beyond this significantly increase late-stage cancer risk (OR 1.48) 3
• Even with a positive FIT and recent colonoscopy, repeat colonoscopy should generally be offered 2

What to Expect

• Among patients with positive FIT, only 2-12% actually have colorectal cancer, meaning 88-98% of positive results are not cancer 3
• However, colonoscopy is still mandatory because advanced adenomas requiring removal are commonly found 3
• If colonoscopy is negative and there are no upper GI symptoms or iron-deficiency anemia, do not pursue upper GI evaluation 2, 3

Special Considerations

When NOT to Use FIT

• Never use FIT in patients with visible blood in stool—proceed directly to colonoscopy 10
• FIT is a screening tool for asymptomatic average-risk individuals, not a diagnostic test for symptomatic patients 10
• In-clinic FOBT during digital rectal examination has extremely poor sensitivity (<10%) and should not be used for screening 4

Tuberculosis Context

• Neither the presence of tuberculosis exposure nor active tuberculosis diagnosis changes the recommendation to use FIT over gFOBT for colorectal cancer screening 1, 2
• Standard colorectal cancer screening guidelines apply to patients with tuberculosis unless they have GI symptoms warranting direct visualization 1

Quality Assurance Targets

• Programs should aim for ≥60% FIT completion rate among those offered testing 2
• Less than 5% of returned FIT samples should be unprocessable 2
• Colonoscopy completion rate for positive FIT should be ≥80% 2
• Adenoma detection rate on follow-up colonoscopy should exceed 45% in men and 35% in women 2